Biovail Corporation, a big pharmaceutical company, recently had its stock downgraded by a well known pharmaceutical analyst and a number of other analysts were also scrutinizing the company. The result wasn't advantageous, their bookkeeping practices were challenged and as the acquisition processes of Biovail were labeled as unethical.
An investor with the firm must determine if she will continue to invest in a company that's been identified with low ethical standards. The supplement Biovail Corporation (B), product 9B04N008 discusses the investor's choice, and some tips that caused her to reconsider that choice.
Publication Date: 04/05/2004
This is just an excerpt. This case is about Finance
